Hunan Nucien Pharmaceutical Co Ltd
Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascula… Read more
Hunan Nucien Pharmaceutical Co Ltd (688189) - Net Assets
Latest net assets as of June 2025: CN¥832.51 Million CNY
Based on the latest financial reports, Hunan Nucien Pharmaceutical Co Ltd (688189) has net assets worth CN¥832.51 Million CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.07 Billion) and total liabilities (CN¥237.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥832.51 Million |
| % of Total Assets | 77.83% |
| Annual Growth Rate | 22.68% |
| 5-Year Change | -45.76% |
| 10-Year Change | N/A |
| Growth Volatility | 117.31 |
Hunan Nucien Pharmaceutical Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Hunan Nucien Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hunan Nucien Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual net assets of Hunan Nucien Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥878.31 Million | -31.68% |
| 2023-12-31 | CN¥1.29 Billion | -0.83% |
| 2022-12-31 | CN¥1.30 Billion | -7.00% |
| 2021-12-31 | CN¥1.39 Billion | -13.91% |
| 2020-12-31 | CN¥1.62 Billion | +353.21% |
| 2019-12-31 | CN¥357.27 Million | +34.91% |
| 2018-12-31 | CN¥264.82 Million | +30.85% |
| 2017-12-31 | CN¥202.38 Million | +18.23% |
| 2016-12-31 | CN¥171.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Nucien Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26379198816.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.46 Billion | 155.88% |
| Total Equity | CN¥936.59 Million | 100.00% |
Hunan Nucien Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hunan Nucien Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NMPGY
PINK:NMPGY
|
$159.21 Million |
|
Aeluma, Inc
NASDAQ:ALMU
|
$159.25 Million |
|
AUPU Home Style Corp Ltd
SHG:603551
|
$159.28 Million |
|
Guangdong Greenway Technology Co Ltd
SHG:688345
|
$159.29 Million |
|
Ibersol SGPS
LS:IBS
|
$159.16 Million |
|
Hennessy Capital Investment Corp. VII Unit
NASDAQ:HVIIU
|
$159.10 Million |
|
Dat Phuong JSC
VN:DPG
|
$159.08 Million |
|
Rongfeng Holding Group
SHE:000668
|
$159.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Nucien Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,303,495,884 to 936,592,122, a change of -366,903,762 (-28.1%).
- Net loss of 356,903,643 reduced equity.
- Dividend payments of 5,226,483 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-356.90 Million | -38.11% |
| Dividends Paid | CN¥5.23 Million | -0.56% |
| Other Changes | CN¥-4.77 Million | -0.51% |
| Total Change | CN¥- | -28.15% |
Book Value vs Market Value Analysis
This analysis compares Hunan Nucien Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.61x to 2.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.72 | CN¥7.94 | x |
| 2018-12-31 | CN¥2.23 | CN¥7.94 | x |
| 2019-12-31 | CN¥3.17 | CN¥7.94 | x |
| 2020-12-31 | CN¥5.82 | CN¥7.94 | x |
| 2021-12-31 | CN¥5.08 | CN¥7.94 | x |
| 2022-12-31 | CN¥4.79 | CN¥7.94 | x |
| 2023-12-31 | CN¥4.75 | CN¥7.94 | x |
| 2024-12-31 | CN¥3.41 | CN¥7.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Nucien Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -135.56%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.31x
- Recent ROE (-38.11%) is below the historical average (2.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 9.51% | 5.25% | 0.45x | 4.00x | CN¥-756.06K |
| 2017 | 15.02% | 7.81% | 0.58x | 3.33x | CN¥9.07 Million |
| 2018 | 22.84% | 7.64% | 1.01x | 2.97x | CN¥30.10 Million |
| 2019 | 27.51% | 9.02% | 1.24x | 2.46x | CN¥58.22 Million |
| 2020 | 8.02% | 12.43% | 0.49x | 1.31x | CN¥-31.61 Million |
| 2021 | -11.62% | -21.77% | 0.35x | 1.53x | CN¥-301.20 Million |
| 2022 | -6.00% | -11.28% | 0.36x | 1.49x | CN¥-210.27 Million |
| 2023 | -0.83% | -1.51% | 0.42x | 1.32x | CN¥-141.22 Million |
| 2024 | -38.11% | -135.56% | 0.22x | 1.31x | CN¥-450.56 Million |
Industry Comparison
This section compares Hunan Nucien Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Nucien Pharmaceutical Co Ltd (688189) | CN¥832.51 Million | 9.51% | 0.28x | $159.21 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |